Cargando…

Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis

IMPORTANCE: One of the most recent treatment regimens used for hormone receptor (HR)–positive, ERBB2 (formerly HER2)–negative metastatic breast cancer is treatment with the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and endocrine therapy (ET). OBJECTIVE: To assess overall survival (OS), pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jinming, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Ahmad, Raees, Yuan, Xinyue, Du, Feng, Zhao, Jiuda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094425/ https://www.ncbi.nlm.nih.gov/pubmed/33048129 http://dx.doi.org/10.1001/jamanetworkopen.2020.20312

Ejemplares similares

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
por: Huo, Xingfa, et al.
Publicado: (2021)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
por: Shen, Guoshuang, et al.
Publicado: (2021)

Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis
por: Huo, Xingfa, et al.
Publicado: (2023)

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
por: Shen, Guoshuang, et al.
Publicado: (2018)

A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis
por: Guo, Xinjian, et al.
Publicado: (2019)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Xin, Yuanfang, et al.
Publicado: (2021)

Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Fuxing, et al.
Publicado: (2021)

Elevated expression of TUBA1C in breast cancer predicts poor prognosis
por: Zhao, Yi, et al.
Publicado: (2023)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy
por: Mouabbi, Jason A., et al.
Publicado: (2023)

Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer
por: Li, Yunhai, et al.
Publicado: (2020)

The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis
por: Tang, Yuyao, et al.
Publicado: (2023)

Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India
por: Ganguly, Sandip, et al.
Publicado: (2022)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
por: Yang, Jiao, et al.
Publicado: (2023)

Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study
por: Ren, Dengfeng, et al.
Publicado: (2021)

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
por: Turner, Nicholas C., et al.
Publicado: (2019)

The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
por: Bao, Kelvin K. H., et al.
Publicado: (2021)

Protein Kinase D Is Dispensable for Development and Survival of Drosophila melanogaster
por: Maier, Dieter, et al.
Publicado: (2019)

Differential Regulation of Cyclin E by Yorkie-Scalloped Signaling in Organ Development
por: Shu, Zhiqiang, et al.
Publicado: (2017)

Distinct and Overlapping Requirements for Cyclins A, B, and B3 in Drosophila Female Meiosis
por: Bourouh, Mohammed, et al.
Publicado: (2016)

Cyclin C Regulated Oxidative Stress Responsive Transcriptome in Mus musculus Embryonic Fibroblasts
por: Stieg, David C., et al.
Publicado: (2019)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Cyclin D1 expression in prostate carcinoma
por: Pereira, R.A., et al.
Publicado: (2014)

Genetic Evidence for Roles of Yeast Mitotic Cyclins at Single-Stranded Gaps Created by DNA Replication
por: Signon, Laurence
Publicado: (2017)

A Cyclin E Centered Genetic Network Contributes to Alcohol-Induced Variation in Drosophila Development
por: Morozova, Tatiana V., et al.
Publicado: (2018)

Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy
por: Fu, Fangmeng, et al.
Publicado: (2022)

Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
por: Li, Xuanyi, et al.
Publicado: (2022)

Proper Cyclin B3 Dosage Is Important for Precision of Metaphase-to-Anaphase Onset Timing in Caenorhabditis elegans
por: Tarailo-Graovac, Maja, et al.
Publicado: (2012)

The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
por: Javed, Aadil, et al.
Publicado: (2023)

Functional Differentiation of Cyclins and Cyclin-Dependent Kinases in Giardia lamblia
por: Kim, Juri, et al.
Publicado: (2023)

Cyclin-dependent kinase 9 is required for the survival of adult Drosophila melanogaster glia
por: Foo, Lynette C.
Publicado: (2017)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors
por: Rao, Xi, et al.
Publicado: (2023)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer
por: Tobias, Claire J., et al.
Publicado: (2020)

Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer
por: Koroukian, Siran M., et al.
Publicado: (2023)

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
por: Husinka, Lakyn, et al.
Publicado: (2020)

Parathyroid Hormone–Related Protein Enhances Human β-Cell Proliferation and Function With Associated Induction of Cyclin-Dependent Kinase 2 and Cyclin E Expression
por: Guthalu Kondegowda, Nagesha, et al.
Publicado: (2010)

MicroRNA-424 serves an anti-oncogenic role by targeting cyclin-dependent kinase 1 in breast cancer cells
por: Xie, Dan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c1kqc874ve5lj44qhnts28fci5